ERBB2 and prostate carcinoma: Similar EMT activation has been observed in HER2-amplified breast cancer cells treated with lapatinib, basal-like breast cancer cells exposed to PI3K/mTOR inhibitors, and paclitaxel-resistant lung or prostate cancer cells tolerating EGFR-TKIs58–60.